佰乐博生物蛋白抗体推荐Research
Grade Bebtelovimab 研究级别药物对照抗体，贝特洛韦单抗
一、中文名称：; LY-3853113; LY-COV1404
二、产品详情：Bebtelovimab 是针对 SARS-CoV-2，特别是 COVID-19 的人源 IgG1-λ2 抗体。Bebtelovimab 能有效中和 SARS-CoV-2 变体，并抑制 COVID-19，具有轻度至中度疗效。
三、产品描述：
货号：DVV00319
表达系统：Mammalian Cells
种属反应性：SARS-CoV-2 (2019-nCoV),
Omicron, BA.4/5 strain, BA.5 strain, BA.4 strain
宿主：Human
同种型：IgG1, lambda2
克隆类型：Monoclonal
靶标：Spike glycoprotein, S
glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike
protein S2', S, 2, Receptor-Binding Domain, RBD
浓度：1.14 mg/ml
内毒素水平：Please contact with the lab
for this information.
纯度：>95% as determined by
SDS-PAGE.
纯化方式：Protein A/G purified from cell
culture supernatant.
Accession号：P0DTC2-2
克隆号：Bebtelovimab
应用：Research Grade Biosimilar
状态：Liquid
保存溶液：0.01M PBS, pH 7.4.
稳定性和存储：Use a manual defrost freezer
and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks).
Store at -20°C 12 months. Store at -80°C long term.
别名：LY-CoV1404, LY3853113
四、参考文献：
Antigenic characterization of the
SARS-CoV-2 Omicron subvariant BA.2.75. PMID: 36108630
Deep mutational scans for ACE2 binding, RBD
expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2
receptor-binding domains. PMID: 36399443
Serious Infusion Reactions in Two Adolescents
Receiving Bebtelovimab. PMID: 36476524
Deep Mutational Scanning to Predict Escape
from Bebtelovimab in SARS-CoV-2 Omicron Subvariants. PMID: 36992294
SABRes: in silico detection of drug resistance
conferring mutations in subpopulations of SARS-CoV-2 genomes. PMID: 37158832
Neutralization sensitivity, fusogenicity, and
infectivity of Omicron subvariants. PMID: 36581867
Evolving Real-World Effectiveness of
Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study. PMID:
37011399
Nirmatrelvir-resistant SARS-CoV-2 variants
with high fitness in an infectious cell culture system. PMID: 36542720
Effectiveness of Bebtelovimab Against
Hospitalization and Death From the Omicron BA.4/BA.5 and BQ.1/BQ.1.1
Subvariants. PMID: 37414096
The effect of bebtelovimab on clinical
outcomes in patients with COVID-19: A meta-analysis. PMID: 37085048
Current Effective Therapeutics in Management
of COVID-19. PMID: 35807123
Allosteric Signal within the Receptor-Binding
Domain of the SARS-CoV-2 Spike Protein Mediated by a Class 3 Monoclonal
Antibody Revealed through Molecular Dynamics Simulations and Protein Residue
Networks. PMID: 38313482
Passive Immunotherapy Against SARS-CoV-2: From
Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of
the Variants. PMID: 35476216
详情请咨询Antibodysystem中国授权总代理-武汉佰乐博生物技术有限公司
网址：https://www.biolabreagent.com/
武汉佰乐博生物技术有限公司作为法国Antibodysystem品牌亚洲区授权总代理。提供近3万种蛋白、抗体等核心生命科学试剂，旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。
试剂 | 耗材 | 定制 | 实验服务 | 供应链
免费热线：027-65279366 /18108604356
